YTEN - Yield10 Bioscience, Inc - Research License deal mit Monsanto (Seite 5)


ISIN: US98585K8624 | WKN: A2PYHH | Symbol: YTEN
6,440
$
17:58:21
Nasdaq
+0,94 %
+0,060 USD

Beitrag schreiben

Begriffe und/oder Benutzer

 

Antwort auf Beitrag Nr.: 59.858.047 von iknowtheway am 12.02.19 22:49:20YOU are not authorized to access this page.
Manchmal braucht man eben etwas Glück :D
Mein Verkaufsorder von 1,70 gestern hatte gezogen. Bin weiterhin von Yield10 überzeugt. Werde in den kommenden Woche wieder eine Position aufbauen.

Mar 15, 2019
Yield10 Bioscience Announces Pricing of $2.9 Million Registered Direct Offering
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Aug 12, 2019
Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C4001

WOBURN, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office allowing its patent application covering the use of C4001 to improve productivity in crops.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience | 0,960 $
Habe hier wieder in den vergangenen Wochen eine Position aufgebaut. Hoffe auf gute news in den kommenden Monaten.

Aug. 12, 2019
Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4285013-yield10-bioscience-…

“CBD is a good example of a product targets for Yield10's traits and capabilities that considerable value for third-party with deep knowledge of the medical CBD business. Yet we're seeing a funded R&D program and upfront payments research funding and license revenues, as appropriate. These product targets provide opportunities for Yield10 to develop businesses that generate product revenue and/or partnerships of downstream revenue. We will keep you posted as it continues to make progress and finalize the business cases.

“And we're also actively engaged in discussions with third parties interested in deploying our traits in a variety of other commercially important crops. We plan to keep you updated on the progress we're making all of these areas in the second half 2019.
Yield10 Bioscience | 0,630 $
Interessante Einschätzung von National Research.

Yield10 Bioscience’s (NASDAQ:YTEN) Buy Rating Reiterated at National Securities
Thursday, September 12th, 2019
https://rivertonroll.com/news/2019/09/12/yield10-bioscience-…

The firm currently has a $5.00 price target company’s stock.

- Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR – €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.
- A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.
- No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.
- Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component.,” National Securities’ analyst wrote.
Yield10 Bioscience | 0,625 €
Neben der Zusammenarbeit mit Bayer/Monsanto hat YTEN auch eine "Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum" vergeben. Forage Genetics ist eine Tochtergesellschaft von Land O’Lakes, Inc. Laut Wikipedia beläuft sich der Jahresumsatz von Land O’Lakes auf 15 Milliarden US-Dollar. Hoffentlich kommen noch mehr solcher Ag industry collaborations.

Link: http://ir.yield10bio.com/node/14091/pdf
Yield10 Bioscience | 0,635 $
Die Aktie könnte mal wieder gute news gebrauchen. 2019 field test results werden für Q4 erwartet.
Yield10 Bioscience | 0,649 $
Oct 23, 2019
Yield10 Bioscience Signs Research Agreement with J. R. Simplot to Evaluate New Traits to Produce High Yielding, Sustainable Potato Crop
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Yield10 Bioscience | 0,621 $
Die Research License mit J. R. Simplot Company ist ein weiterer großer Gewinn für YTEN. Die J. R. Simplot Company ist ein milliardenschweres Unternehmen und ein großer Anbieter von Kartoffeln.

https://en.wikipedia.org/wiki/Simplot

Unter anderem ist die J. R. Simplot Company ein großer Lieferant von Pommes für McDonald's.
Yield10 Bioscience | 0,565 €


Beitrag zu dieser Diskussion schreiben